Rejuveron Transitions to Become a Clinical Stage Company as Rejuvenate Biomed Starts Ground-breaking Clinical Trial in Age-Related Muscle Wasting Disease, Sarcopenia
press release · REJ-22-01
Schlieren, Zürich, Switzerland · 29 March 2022
Rejuveron Life Sciences AG (‘Rejuveron’), a Zürich-based biotechnology company developing therapies to promote healthy aging, today announced that Rejuvenate Biomed NV (‘Rejuvenate’) has commenced its first Phase 1 clinical trial assessing the company’s lead candidate RJx-01 for the treatment of sarcopenia.
This is the first program in the Rejuveron pipeline to enter clinical trials and marks its maturation from a preclinical to clinical stage company. Rejuveron was a lead investor in Rejuvenate’s €15.7 million Series B funding in October 2021 and will ultimately acquire a majority shareholding.
See the Rejuvenate full press release here.
Dr. Matthias Steger, PhD, MBA, CEO of Rejuveron said:
“Over the past four years, the Rejuvenate team has demonstrated that its approach can be used to develop new patent-protected combination drugs based on known prescription medicines. This platform has resulted in a promising first drug candidate, with the wider application being to deliver therapeutics with a meaningful impact on the treatment and prevention of multiple age-related diseases by tackling their root causes. This strikes right at the heart of Rejuveron’s purpose: making therapies happen for people to stay healthier for longer.